ISRCTN46791858进行中（未招募）1 期
Phase I trial, Quotient code: QSC301137 [The full scientific title will be published within 30 months after the end of the trial]
iminal BioSciences (United Kingdom)0 个研究点目标入组 88 人开始时间: 2023年11月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
排除标准
- •The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
1 期
Phase I trial: Quotient code QSC301152Healthy volunteersISRCTN65070683ovartis (Switzerland)88
进行中（未招募）
1 期
Phase I trial, Quotient Code: QSC300720The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN57359805Veradermics Inc16
进行中（未招募）
1 期
Phase I trial, Quotient Code: QSC300414The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN85847953D. E. Shaw Research104
进行中（未招募）
1 期
Phase I trial: Quotient Code QSC207871The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN12178605ovartis Pharma AG43
进行中（未招募）
1 期
Phase I trial: Quotient code QSC301813The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN90651766Carmot Therapeutics (United States)14